Summary

Overview
Global Transcatheter Valve Repair System Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Transcatheter valve repair systems are minimally invasive devices used to treat heart valve diseases like aortic stenosis, mitral regurgitation, and tricuspid regurgitation without open-heart surgery. They involve inserting a catheter through a small incision in the leg or chest, guiding it to the heart using imaging guidance, and then deploying a repair device over the damaged valve, either repairing it or replacing it with a new one.
Market Dynamics: Drivers and Restraints
Rise in the advancements in the systems
New transcatheter valve repair systems are being developed with enhanced functionality and durability, reducing the risk of structural valve deterioration. These advancements have increased the global adoption of these systems, enhancing their efficiency and effectiveness.
One of the most notable advancements is 3D printing for customized valve implants Advancements in 3D printing technology have opened new horizons in the field of healt valve replacement. Cardiologists and surgeons can now create custom-made health valve implants tailored to an individual patient's unique anatomy. This personalisation improves the implant's fit and function, enhancing the overall success of the procedure.
Furthermore, the transcatheter valve repair system market is also driven by various other factors like a rise in the prevalence of cardiovascular diseases, an increase in R&D investment and others that help the market to grow during the forecast period.
Market Dynamics: Restraint
The market is hampered by various factors in that the high cost of the systems and procedures is the main factor that hinders the market growth during the forecast period. For example, the initial costs for the TMVr procedure and index hospitalization were $35 755 and $48 198, respectively.
Segment Analysis
The global transcatheter valve repair system market is segmented based on product type, application, end-user and region.
The transcatheter aortic valve replacement from the product type segment accounted for approximately 43.7% of the transcatheter valve repair system market share
The transcatheter aortic valve replacement from the product type segment accounted for approximately 43.7% and is expected to dominate during the forecast period. Transcatheter aortic valve replacement (TAVR) is a procedure to replace an aortic valve that is narrowed and doesn't open fully. The aortic valve is between the left lower heart chamber and the body's main artery. The narrowing of the aortic valve is called aortic valve stenosis. The valve problem blocks or slows blood flow from the heart to the body.
For instance, in September 2022, Medtronic stated the expanded U.S. market release of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut™ FX TAVR system. Evolut FX adds new features to the existing Evolut platform to enhance ease of use and predictable valve deployment for physicians.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors like novel device launches, increase in incidence of heart diseases, presence of major vendors, and rise in investment in R&D activities are boosting market statistics in the region.
For instance, in January 2024, Eisenhower Health was the first hospital in the United States to become an Edwards Benchmark program Case Observation Site for the treatment of aortic stenosis in patients undergoing transcatheter aortic valve replacement (TAVR).
The standard treatment for aortic stenosis (a narrowing of the aortic valve opening) has been valve replacement through open-heart surgery. In 2015, Eisenhower Health became the first and remains the only hospital in the Coachella Valley to approach aortic stenosis with TAVR.
COVID-19 Impact Analysis
Covid 19 had a significant impact on the transcatheter valve repair system market where covid 19 pandemic has significantly postponed millions of elective procedures, particularly aortic valve replacement procedures with higher postponement for surgical procedures than transcatheter ones, and less pronounced during the second wave.
Market Segmentation
By Product Type
• Transcatheter Aortic Valve Replacement (TAVR)
• Transcatheter Mitral Valve Replacement (TMVR)
• Transcatheter Pulmonary Valve Replacement (TPVR)
• Transcatheter Tricuspid Valve Replacement (TTVR)
By Application
• Aortic Stenosis
• Mitral Stenosis
• Tricuspid Stenosis
• Pulmonary Stenosis
By End-user
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Abbott Laboratories, Biotronik Pvt. Ltd., Colibri Heart Valve, Edwards Lifesciences Corporation, Medtronic plc, Neovasc lnc, Boston Scientific, Cromaze Technologies, Microport Scientific Corporation, Venus Medtech (Hangzhou) Inc among others.
Key Developments
 In October 2023, Edwards Lifesciences Corporation stated the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter treatment of eligible patients with tricuspid regurgitation (TR). The EVOQUE system is the world's first transcatheter valve replacement therapy to receive regulatory approval to treat TR.
 In September 2022, Edwards Lifesciences Corporation stated the company's PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).
Why Purchase the Report?
• To visualize the global transcatheter valve repair system market segmentation based on product type, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of transcatheter valve repair system market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global transcatheter valve repair system market report would provide approximately 69 tables, 70 figures and 183 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the advancements in the systems
4.1.1.2. Rise in the prevalence of cardiovascular diseases
4.1.2. Restraints
4.1.2.1. High cost associated with the systems
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Transcatheter Aortic Valve Replacement (TAVR)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Transcatheter Mitral Valve Replacement (TMVR)
7.4. Transcatheter Pulmonary Valve Replacement (TPVR)
7.5. Transcatheter Tricuspid Valve Replacement (TTVR)
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Aortic Stenosis *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Mitral Stenosis
8.4. Tricuspid Stenosis
8.5. Pulmonary Stenosis
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Ambulatory Surgical Centers
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Abbott Laboratories *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Biotronik Pvt. Ltd.
12.3. Colibri Heart Valve
12.4. Edwards Lifesciences Corporation
12.5. Medtronic plc
12.6. Neovasc lnc
12.7. Boston Scientific
12.8. Cromaze Technologies
12.9. Microport Scientific Corporation
12.10. Venus Medtech (Hangzhou) Inc
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us